Nestlé Targets Diabetes Prevention With French Partner
Nestlé Health Science is putting its financial weight behind the commercialization of a plant combination product which has shown in trials to reduce the risk factors for type 2 diabetes.
You may also be interested in...
Valbiotis and Nestlé Health Science plan to launch in 2024 a dietary supplement targeted at sufferers of prediabetes and type-2 diabetes following positive results from a recent study which showed the product's efficacy on key markers of glucose metabolism.
Nestle Health Science has expanded its nutritional footprint steadily since 2017 but investing in Orgain, with option to fully acquire in 2024 brings its first business working exclusively with plant-based ingredients.
Atrium expects to scale its nutrition personalization services by integrating LivingMatrix with its PureGenomics platform, which combines educational tools, protocols and core products with a practitioner website application to help identify and address single nucleotide polymorphisms.